H3-D is the first drug discovery centre in Africa, with an initial research focus on TB and malaria, two top medical needs on the continent. Last year, the first compound developed by H3-D was endorsed by the Medicines for Malaria Venture as a pre-clinical anti-malarial candidate.
Through this partnership, Novartis supports the Centre’s efforts to bridge the gap between basic and clinical studies, training a new generation of African scientists with key skills required for drug discovery and development – integrating medicinal chemistry, disease biology, and pharmacology.
For example, through this collaboration Novartis helped H3-D to develop an FDA-level clinical site to conduct Phase I clinical studies of new medicines discovered by the Centre in Cape Town, South Africa. Additionally, Novartis supports H3-D in the design of medicines against tuberculosis (TB), and conduct joint programs on malaria research with the Singapore-based Novartis Institute for Tropical Diseases (NITD).
|Location||South Africa, Southern Africa|